Lorecivivint

DB14883InvestigationalSmall molecule

Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).

Mechanism: Pharmacologically active on Dual specificity tyrosine-phosphorylation-regulated kinase 1A and Dual specificity protein kinase CLK2
Curator reviewed
Formula / weight: C₂₉H₂₄FN₇O · 505.557 g/mol (avg)
Code names: SM04690

Resolves to

Compound

UNII42EK42WHI5CAS1467093-03-3

Structure

InChIKeyAQDWDWAYVBQMAM-UHFFFAOYSA-NSMILESCC(C)CC(=O)NC1=CC(=CN=C1)C1=CC2=C(NN=C2C2=NC3=C(C=NC=C3N2)C2=CC=CC(F)=C2)C=C1

Targets

Q13627DYRK1AP49760CLK2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lorecivivint, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account